This study structurally estimates a dynamic model of drug development
process in pharmaceutical industry, and uses counterfactual experiments to
evaluate effects of various policy interventions aimed at increasing the introduction rate of new drugs within a specifi…c therapeutic area. Advanced computational methods --such as continuous time and polynomial approximations
--overcome the modeling difficulties that limited previous studies to one or two
stages of development process, and allow the model to describe the progress of
drugs through all three phases of clinical trials and FDA approval. The primary result is that most policies affecting earlier stages of drug development
are less effective than those aimed at later stages. The reason for this …finding
is a strategic response to policy-induced changes in the number of drugs under
development and on the market.